Create a narrative

Ionis Pharmaceuticals Community

NasdaqGS:IONS Community

1 Narratives written by author
0 Comments on narratives written by author
14 Fair Values set on narratives written by author

Create a narrative

Ionis Pharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 26 Analysts

Licensing Deals And TRYNGOLZA Launch Will Expand Global Presence

Key Takeaways Strategic licensing and partnerships are set to enhance revenue potential, cash flow, and international earnings, improving the company's financial outlook. Expansion through new and planned product launches, complemented by promising Phase III trials, could drive growth in revenues and net margins.

US$57.31

FV

41.4% undervalued

18.81%

Revenue growth p.a.

0

0

9

17 days ago